2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Transplantation, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Genetic Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, MDS, MPN, CML, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2819 Risk and outcomes of subsequent chronic myeloid leukemia, myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasm overlap among cancer survivors in the United States: A population-based SEER analysis

Debolina Pramanik, Internal Medicine Resident, Yanwen Chen, MS2, Shramana Sarkar3, Kristina Nasr, MD4, Aarushi Venkatraman5, Viktoriya Partyka, MD6, Anthony Maurice Navarrete, MD7, Aaron T. Gerds, MD, MS8, Hetty Carraway, MD, MBA9, Abhay Singh, MD, MPH10, Moaath Mustafa Ali, MD, MPH11, Anjali Sunder Advani, MD12, John Carlos Molina, MD, MEd13, Sophia Rebecca Balderman, MD14, Akriti G Jain, MD, FACP15, Sudipto Mukherjee, MD, PhD, MPH16
1 Cleveland Clinic Foundation, Cleveland, Ohio, United States
2 Cleveland Clinic Foundation, Cleveland, Ohio, United States
3 Saint Vincent Hospital, Worcester, Massachusetts, United States
4 Cleveland Clinic Foundation, Cleveland, Ohio, United States
5 Cleveland Clinic Foundation, Cleveland, Ohio, United States
6 Cleveland Clinic Foundation, Cleveland, Ohio, United States
7 Ascension St Joseph, Chicago, United States
8 Cleveland Clinic Foundation, Cleveland, Ohio, United States
9 Cleveland Clinic Foundation, Cleveland, Ohio, United States
10 Cleveland Clinic Foundation, Cleveland, Ohio, United States
11 Cleveland Clinic Foundation, Cleveland, Ohio, United States
12 Cleveland Clinic Foundation, Cleveland, Ohio, United States
13 Cleveland Clinic Foundation, Cleveland, Ohio, United States
14 Cleveland Clinic Foundation, Cleveland, Ohio, United States
15 Cleveland Clinic Foundation, Cleveland, Ohio, United States
16 Cleveland Clinic Foundation, Cleveland, Ohio, United States

INTRODUCTION

Although therapy-related myeloid neoplasms are well recognized, the risk of subsequent myeloproliferative neoplasms (MPNs) among cancer survivors remains poorly defined, particularly in the era of targeted therapies and improved survivorship. With a growing population of cancer survivors in the US, defining this risk is essential to inform survivorship care, and improve long-term outcomes.

METHODS

Using SEER 17 registries (2000–2021), we identified patients aged ≥15 years with primary solid malignancies (12 cancer sites), lymphomas, or myeloma and followed them for second primary MPNs diagnosed ≥1 year after the index cancer. MPNs included chronic myeloid leukemia (CML), Philadelphia-negative MPNs (Ph-neg MPNs), and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. Patients with primary non-myelogenous leukemias, acute myeloid leukemia, or MDS, and those with third or higher-order MPNs, were excluded. Cancers were classified using ICD-O-3/WHO 2008 criteria. Standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) quantified excess relative risk compared with the general US population, adjusted for age, sex, race, and calendar year. Competing-risk cumulative incidence functions estimated the absolute probability of MPNs, treating death and non-MPN second cancers as competing events, while multivariable Fine–Gray regression identified independent predictors of cumulative MPN incidence, adjusting for age, sex, race/ethnicity, latency, year of diagnosis, and initial treatment [(radiation therapy (XRT), chemotherapy (C), both (XRT+C), or neither] separately for primary solid and hematologic malignancies (combined lymphomas and myeloma). Overall survival from second primary MPN diagnosis was compared with de novo myeloid neoplasms. Analyses were performed using SEER*Stat 8.4.5 and R version 4.2.2.

RESULTS

Among 4,538,217 cancer survivors with 31,504,775 person-years of follow-up, 1,443 developed CML and 4,051 developed Ph-neg MPNs or MDS/MPN overlap, with incidence rates of 4.58 (95% CI, 4.34–4.82) and 12.74 (95% CI, 12.34–13.12) per 100,000 person years, respectively. Among MPN pts, 55.5% were male, 68.9% non-Hispanic White, 33.3% received XRT, and 30.8% received C. Compared with the general population, SIR for CML was increased after solid (1.42; 95% CI, 1.35–1.50) and hematologic malignancies (1.53; 95% CI, 1.23–1.88). The top five primary sites with highest SIRs for CML were ear, nose, and throat (1.86; 95% CI, 1.40–2.43), respiratory (2.00; 95% CI, 1.56–2.52), soft tissue (1.94; 95% CI, 1.04–3.33), endocrine (2.78; 95% CI, 2.26–3.37), and lymphoid cancers (1.66; 95% CI, 1.32–2.07). The only site with elevated SIR for Ph-neg MPNs plus MDS/MPN overlap was urinary system (1.21; 95% CI, 1.10–1.34). Elevated SIR for CML was observed regardless of the treatment modality received (including those without XRT + C) with highest risk observed after XRT without C (1.72; 95% CI, 1.55–1.90). In contrast, MDS/MPN overlap risk increased after C without XRT (1.25; 95% CI, 1.07–1.46), whereas risk of Ph-neg MPN was not affected by treatment received. After competing-risk adjustment, 10-year CI for CML (for both solid and hematological) and other MPN entities (for both solid and hematological) were 0.03% and 0.08% respectively. In adjusted regression analyses, older age (vs < 60 year age groups), male sex, non-Hispanic White race, shorter latency (1-5 years), and earlier diagnosis era (vs 2016-2021) independently predicted higher MPN risk after both solid and hematologic malignancies. There was no consistent directionality of association by treatment groups. 10-year OS was lower for subsequent CML than for de novo CML (49% vs 65%, p<0.05), and for subsequent Ph-negative MPN plus MDS/MPN overlap than for de novo disease (32% vs 59%, p<0.05).

 CONCLUSION

Cancer survivors face an increased relative risk of CML regardless of treatment particularly after endocrine, respiratory, and soft tissue malignancies — suggesting an inherent susceptibility that is further magnified by XRT. Notably, the urinary system was the only site associated with an elevated relative risk for Ph-neg MPNs and MDS/MPN overlap syndromes. While absolute risks remain very low at approximately 3 per 10,000 at 10 years, survivors who develop these subsequent malignancies face significantly inferior survival compared to those with de novo disease.  

 

Debolina Pramanik, Internal Medicine Resident: No relevant conflicts of interest to declare.